Two recent studies have shown further evidence that antidepressant drugs can modulate central NLRP3 inflammasome activation, microglial structure and function (Pan et al., 2014; Du et al., 2016), thereby suggesting the therapeutic potential of targeting neuroinflammation to treat depression. Here, NLRP3 is linked to depressive disorder.